IP Library › Granted Patent US 12,415,844
Granted Patent B2
US 12,415,844 · App. 16/772,262 · Granted Sep 16, 2025

BCMA specific VCAR compositions and methods for use

Inventors: Eric M. Ostertag (San Diego, CA); Devon Shedlock (San Diego, CA)
Assignee: Poseida Therapeutics, Inc.
C07K14/7051A61K40/11A61K40/31A61K40/4211A61K40/4215C07K14/70517C07K16/44C12N5/0636C07K2317/24C07K2317/565C07K2319/03
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,415,844
App. No.
16/772,262
Granted
Sep 16, 2025
Kind
B2
Abstract

Disclosed are VHH chimeric antigen receptors (VCARs), VCAR transposons encoding VCARs of the disclosure, cells modified to express VCARs of the disclosure, as well as methods of making and methods of using the same for adoptive cell therapy.

Claims (97)

1. A cell comprising a chimeric antigen receptor (CAR) comprising:

(a) an ectodomain comprising an antigen recognition region, wherein the antigen recognition region comprises at least one VH that specifically binds to B-Cell Maturation Antigen (BCMA);

(b) a transmembrane domain, and

(c) an endodomain comprising at least one costimulatory domain;

wherein the VH comprises:

a complementarity determining region 1 (CDR1) comprising an amino acid sequence of SEQ ID NO: 18056;

a complementarity determining region 2 (CDR2) comprising an amino acid sequence of SEQ ID NO: 18060; and

a complementarity determining region 3 (CDR3) comprising an amino acid sequence of SEQ ID NO: 18064.

2. The cell of claim 1 , wherein the VH comprises or consists of a recombinant or chimeric sequence.

3. The cell of claim 1 , wherein the VH comprises or consists of a human or humanized sequence.

4. The cell of claim 1 , wherein the ectodomain of (a) further comprises a signal peptide.

5. The cell of claim 1 , wherein the ectodomain of (a) further comprises a hinge between the antigen recognition region and the transmembrane domain.

6. The cell of claim 4 , wherein the signal peptide comprises an amino acid sequence of a human CD2, CD3δ, CD3ε, CD3γ, CD3ζ, CD4, CD8α, CD19, CD28, 4-1BB or GM-CSFR signal peptide.

7. The cell of claim 6 , wherein the signal peptide comprises an amino acid sequence of a human CD8a signal peptide.

8. The cell of claim 7 , wherein the human CD8a signal peptide comprises an amino acid sequence of SEQ ID NO: 18012.

9. The cell of claim 1 , wherein the transmembrane domain comprises an amino acid sequence of a human CD2, CD3δ, CD3ε, CD3γ, CD3ζ, CD4, CD8α, CD19, CD28, 4-1BB or GM-CSFR transmembrane domain.

10. The cell of claim 9 , wherein the transmembrane domain comprises an amino acid sequence of a human CD8a transmembrane domain.

11. The cell of claim 10 , wherein the human CD8a transmembrane domain comprises an amino acid sequence of SEQ ID NO: 18014.

12. The cell of claim 1 , wherein the endodomain comprises an amino acid sequence of a human CD3ζ endodomain.

13. The cell of claim 1 , wherein the at least one costimulatory domain comprises an amino acid sequence of a human 4-1BB, CD28, CD40, ICOS, MyD88, OX-40 intracellular segment, or any combination thereof.

14. The cell of claim 13 , wherein the at least one costimulatory domain comprises an amino acid sequence of a human 4-1BB costimulatory domain.

15. The cell of claim 12 , wherein the human CD35 endodomain comprises an amino acid sequence of SEQ ID NO: 18016.

16. The cell of claim 14 , wherein the human 4-1BB costimulatory domain comprises an amino acid sequence of SEQ ID NO: 18018.

17. The cell of claim 5 , wherein the hinge comprises an amino acid sequence of a human CD8α, IgG4, CD4 hinge or any combination thereof.

18. The cell of claim 17 , wherein the hinge comprises an amino acid sequence of a human CD8α hinge.

19. The cell of claim 18 , wherein the human CD8α comprises an amino acid sequence of SEQ ID NO: 18020.

20. A composition comprising the cell of claim 1 and at least one pharmaceutically acceptable carrier.

21. The cell of claim 1 , wherein the cell is an immune cell.

22. The cell of claim 21 , wherein the immune cell is a T-cell, a Natural Killer (NK) cell, a Natural Killer (NK)-like cell, a Cytokine Induced Killer (CIK) cell, a hematopoietic progenitor cell, a peripheral blood (PB) derived T cell or an umbilical cord blood (UCB) derived T-cell.

23. The cell of claim 1 , wherein the cell is autologous.

24. The cell of claim 1 , wherein the cell is allogeneic.

25. A composition comprising a population of cells, wherein a plurality of cells of the population comprises the cell of claim 1 .

26. The cell of claim 1 , wherein the VH comprises an amino acid sequence of SEQ ID NO: 18051.

27. The cell of claim 1 , wherein the CAR comprises comprises amino acids 22-362 of the amino acid sequence of SEQ ID NO: 18006.

28. A cell comprising a chimeric antigen receptor (CAR) comprising:

(a) an ectodomain comprising an antigen recognition region, wherein the antigen recognition region comprises at least one VH that specifically binds to BCMA and wherein the VH comprises an amino acid sequence of SEQ ID NO: 18051;

(b) a hinge domain comprising a human CD8α hinge domain;

(c) a transmembrane domain comprising a human CD8α transmembrane domain; and

(d) an endodomain comprising a human 4-1BB costimulatory domain and a human CD3ζ endodomain.

29. The cell of claim 28 , wherein the human CD8α hinge domain comprises the amino acid sequence of SEQ ID NO: 18020, wherein the human CD8α transmembrane domain comprises the amino acid sequence of SEQ ID NO: 18014, wherein the human 4-1BB costimulatory domain comprises the amino acid sequence of SEQ ID NO: 18018, and wherein the human CD3ζ endodomain comprises the amino acid sequence of SEQ ID NO: 18016.

30. The cell of claim 28 , wherein the cell is an immune cell.

31. The cell of claim 30 , wherein the immune cell is a T-cell, a Natural Killer (NK) cell, a Natural Killer (NK)-like cell, a Cytokine Induced Killer (CIK) cell, a hematopoietic progenitor cell, a peripheral blood (PB) derived T cell or an umbilical cord blood (UCB) derived T-cell.

32. The cell of claim 31 , wherein the immune cell is a T cell.

33. The cell of claim 32 , wherein the immune cell is allogeneic.

34. The cell of claim 27 , wherein the cell is a T cell.

35. The cell of claim 34 , wherein the T cell is a memory stem T cell (T SCM ).

36. The cell of claim 35 , wherein the T SCM is allogeneic.

37. The cell of claim 27 , wherein the cell further comprises an exogenous gene that confers resistance to a deleterious compound.

38. The cell of claim 37 , wherein the gene is a Dihydrofolate Reductase (DHFR) gene.

39. The cell of claim 27 , wherein the cell further comprises an exogenous inducible proapoptotic polypeptide.

40. The cell of claim 39 , wherein the inducible proapoptotic polypeptide comprises a truncated caspase 9 polypeptide.

41. A composition comprising the cell of claim 29 and at least one pharmaceutically acceptable carrier.

42. A composition comprising the cell of claim 33 and at least one pharmaceutically acceptable carrier.

43. A composition comprising a population of cells, wherein a plurality of cells of the population comprises the cell of claim 29 .

44. A composition comprising a population of cells, wherein a plurality of cells of the population comprises the cell of claim 33 .

45. The cell of claim 1 , wherein the CAR comprises an amino acid sequence of SEQ ID NO: 18006.

46. The cell of claim 28 , wherein the ectodomain further comprises a human CD8a signal peptide.

47. The cell of claim 46 , where in the human CD8a signal peptide comprises the amino acid sequence of SEQ ID NO: 18012.

48. The cell of claim 27 , wherein the cell is an allogeneic T-cell.

49. The cell of claim 48 , wherein the cell further comprises an exogenous gene that confers resistance to a deleterious compound.

50. The cell of claim 49 , wherein the gene is a Dihydrofolate Reductase (DHFR) gene.

51. The cell of claim 48 , wherein the cell further comprises an exogenous inducible proapoptotic polypeptide, wherein the inducible proapoptotic polypeptide comprises a truncated caspase 9 polypeptide.

52. The cell of claim 50 , wherein the cell further comprises an exogenous inducible proapoptotic polypeptide, wherein the inducible proapoptotic polypeptide comprises a truncated caspase 9 polypeptide.

53. A composition comprising a population of cells, wherein a plurality of cells of the population comprises the cell of claim 50 .

54. A composition comprising a population of cells, wherein a plurality of cells of the population comprises the cell of claim 52 .

55. A composition comprising a population of cells, wherein a plurality of cells of the population comprises the cell of claim 49 .

56. The cell of claim 49 , wherein the DHFR gene comprises the sequence of SEQ ID NO: 17012.

57. The cell of claim 48 , wherein the truncated caspase 9 polypeptide comprises the sequence of SEQ ID NO: 18028.

58. The cell of 50 , wherein the truncated caspase 9 polypeptide comprises the sequence of SEQ ID NO: 18028.

59. A nucleic acid encoding a chimeric antigen receptor (CAR) comprising:

(a) an ectodomain comprising an antigen recognition region, wherein the antigen recognition region comprises at least one VH that specifically binds to B-Cell Maturation Antigen (BCMA);

(b) a transmembrane domain, and

(c) an endodomain comprising at least one costimulatory domain;

wherein the VH comprises:

a complementarity determining region 1 (CDR1) comprising an amino acid sequence of SEQ ID NO: 18056;

a complementarity determining region 2 (CDR2) comprising an amino acid sequence of SEQ ID NO: 18060; and

a complementarity determining region 3 (CDR3) comprising an amino acid sequence of SEQ ID NO: 18064.

60. The nucleic acid of claim 59 , wherein the ectodomain of (a) further comprises a signal peptide.

61. The nucleic acid of claim 59 , wherein the ectodomain of (a) further comprises a hinge between the antigen recognition region and the transmembrane domain.

62. The nucleic acid of claim 60 , wherein the signal peptide is a human CD8α signal peptide.

63. The nucleic acid of claim 59 , wherein the transmembrane domain comprises a human CD8α transmembrane domain.

64. The nucleic acid of claim 59 , wherein the endodomain comprises a human CD3ζ endodomain.

65. The nucleic acid of claim 59 , wherein the at least one costimulatory domain comprises an amino acid sequence of a human 4-1 BB costimulatory domain.

66. The nucleic acid of claim 59 , wherein the hinge comprises an amino acid sequence of a human CD8α hinge.

67. The nucleic acid of claim 59 , wherein the VH comprises the amino acid sequence of SEQ ID NO: 18051.

68. The nucleic acid of claim 59 , wherein the CAR comprises the amino acid sequence of SEQ ID NO: 18006.

69. The nucleic acid of claim 59 comprising the sequence of SEQ ID NO: 18007.

70. A transposon comprising the nucleic acid of claim 59 .

71. The transposon of claim 70 , wherein the transposon is a piggyBac transposon.

72. The nucleic acid of claim 68 , wherein the polynucleotide further comprises an exogenous gene that confers resistance to a deleterious compound.

73. The nucleic acid of claim 72 , wherein the gene is a Dihydrofolate Reductase (DHFR) gene.

74. The nucleic acid of claim 68 , wherein the polynucleotide further encodes an exogenous inducible proapoptotic polypeptide, wherein the inducible proapoptotic polypeptide comprises a truncated caspase 9 polypeptide.

75. The nucleic acid of claim 73 , wherein the polynucleotide further encodes an exogenous inducible proapoptotic polypeptide, wherein the inducible proapoptotic polypeptide comprises a truncated caspase 9 polypeptide.

76. A transposon comprising the nucleic acid of claim 73 .

77. The transposon of claim 76 , wherein the transposon is a piggyBac transposon.

78. A transposon comprising the nucleic acid of claim 75 .

79. The transposon of claim 78 , wherein the transposon is a piggyBac transposon.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2021
From: OSTERTAG, ERIC M.; SHEDLOCK, DEVON
To: POSEIDA THERAPEUTICS, INC.
Reel/Frame 055549/0973 →
Continuity (3)
Provisional Application 62608894 · Dec 21, 2017
Provisional Application 62608571 · Dec 20, 2017
Related Publication 20210139557A1 · May 13, 2021
References Cited (254)
US 3773919A · Boswell et al. · 1973 [cited by applicant]
US 4239754A · Sache et al. · 1980 [cited by applicant]
US 4309989A · Fahim · 1982 [cited by applicant]
US 4589330A · Teron · 1986 [cited by applicant]
US 4656134A · Ringold · 1987 [cited by applicant]
US 4668218A · Virtanen · 1987 [cited by applicant]
US 4683195A · Mullis et al. · 1987 [cited by applicant]
US 4683202A · Mullis · 1987 [cited by applicant]
US 4704692A · Ladner · 1987 [cited by applicant]
US 4766067A · Biswas · 1988 [cited by applicant]
US 4767402A · Kost et al. · 1988 [cited by applicant]
US 4795699A · Tabor et al. · 1989 [cited by applicant]
US 4800159A · Mullis et al. · 1989 [cited by applicant]
US 4818542A · DeLuca et al. · 1989 [cited by applicant]
US 4889818A · Gelfand et al. · 1989 [cited by applicant]
US 4921794A · Tabor et al. · 1990 [cited by applicant]
US 4925673A · Steiner et al. · 1990 [cited by applicant]
US 4939666A · Hardman · 1990 [cited by applicant]
US 4946778A · Ladner et al. · 1990 [cited by applicant]
US 4965188A · Mullis et al. · 1990 [cited by applicant]
US 4994370A · Silver et al. · 1991 [cited by applicant]
US 5066584A · Gyllensten et al. · 1991 [cited by applicant]
US 5091310A · Innis · 1992 [cited by applicant]
US 5122464A · Wilson et al. · 1992 [cited by applicant]
US 5130238A · Malek et al. · 1992 [cited by applicant]
US 5142033A · Innis · 1992 [cited by applicant]
US 5168062A · Stinski · 1992 [cited by applicant]
US 5223409A · Ladner et al. · 1993 [cited by applicant]
US 5260203A · Ladner et al. · 1993 [cited by applicant]
US 5266491A · Nagata et al. · 1993 [cited by applicant]
US 5385839A · Stinski · 1995 [cited by applicant]
US 5403484A · Ladner et al. · 1995 [cited by applicant]
US 5404871A · Goodman et al. · 1995 [cited by applicant]
US 5427908A · Dower et al. · 1995 [cited by applicant]
US 5455030A · Ladner et al. · 1995 [cited by applicant]
US 5458135A · Patton et al. · 1995 [cited by applicant]
US 5514670A · Friedman et al. · 1996 [cited by applicant]
US 5518889A · Ladner et al. · 1996 [cited by applicant]
US 5534621A · Ladner et al. · 1996 [cited by applicant]
US 5571698A · Ladner et al. · 1996 [cited by applicant]
US 5576195A · Robinson et al. · 1996 [cited by applicant]
US 5580717A · Dower et al. · 1996 [cited by applicant]
US 5580734A · Treco et al. · 1996 [cited by applicant]
US 5595898A · Robinson et al. · 1997 [cited by applicant]
US 5618920A · Robinson et al. · 1997 [cited by applicant]
US 5641670A · Treco et al. · 1997 [cited by applicant]
US 5643768A · Kawasaki · 1997 [cited by applicant]
US 5656730A · Lee · 1997 [cited by applicant]
US 5658754A · Kawasaki · 1997 [cited by applicant]
US 5693493A · Robinson et al. · 1997 [cited by applicant]
US 5698417A · Robinson et al. · 1997 [cited by applicant]
US 5698435A · Robinson et al. · 1997 [cited by applicant]
US 5733761A · Treco et al. · 1998 [cited by applicant]
US 5750373A · Garrard et al. · 1998 [cited by applicant]
US 5763733A · Whitlow et al. · 1998 [cited by applicant]
US 5767260A · Whitlow et al. · 1998 [cited by applicant]
US 5770222A · Unger et al. · 1998 [cited by applicant]
US 5770359A · Wilson et al. · 1998 [cited by applicant]
US 5814599A · Mitragotri et al. · 1998 [cited by applicant]
US 5827739A · Wilson et al. · 1998 [cited by applicant]
US 5837500A · Ladner et al. · 1998 [cited by applicant]
US 5839446A · Waner et al. · 1998 [cited by applicant]
US 5849695A · Cohen et al. · 1998 [cited by applicant]
US 5851198A · Castellano et al. · 1998 [cited by applicant]
US 5856456A · Whitlow et al. · 1999 [cited by applicant]
US 5871753A · Crabtree et al. · 1999 [cited by applicant]
US 5879681A · Leone-Bay et al. · 1999 [cited by applicant]
US 5885793A · Griffiths et al. · 1999 [cited by applicant]
US 6019968A · Plaz et al. · 2000 [cited by applicant]
US 6309663B1 · Patel et al. · 2001 [cited by applicant]
US 9393292B2 · Brenner · 2016 [cited by applicant]
US 9913882B2 · Slawin et al. · 2018 [cited by applicant]
US 10041077B2 · Minshull et al. · 2018 [cited by applicant]
US 20150051266A1 · Kochenderfer · 2015 [cited by applicant]
US 20190177421A1 · Ostertag et al. · 2019 [cited by applicant]
US 20200138865A1 · Kochenderfer · 2020 [cited by examiner]
US 20230190811A1 · Ostertag et al. · 2023 [cited by applicant]
CN 106163547A · 2016 [cited by applicant]
CN 106687483A · 2017 [cited by applicant]
CN 106795217A · 2017 [cited by applicant]
EP 0237507B1 · 1991 [cited by applicant]
JP 2020505001A · 2020 [cited by applicant]
WO WO9117271A1 · 1991 [cited by applicant]
WO WO9118980A1 · 1991 [cited by applicant]
WO WO9119818A1 · 1991 [cited by applicant]
WO WO9205258A1 · 1992 [cited by applicant]
WO WO9214843A1 · 1992 [cited by applicant]
WO WO9216221A1 · 1992 [cited by applicant]
WO WO9308278A1 · 1993 [cited by applicant]
WO WO9406498A1 · 1994 [cited by applicant]
WO WO9408552A2 · 1994 [cited by applicant]
WO WO9416970A1 · 1994 [cited by applicant]
WO WO9619256A1 · 1996 [cited by applicant]
WO WO9722376A1 · 1997 [cited by applicant]
WO WO9725086A2 · 1997 [cited by applicant]
WO WO9835888A1 · 1998 [cited by applicant]
WO WO9853847A1 · 1998 [cited by applicant]
WO WO9916419A1 · 1999 [cited by applicant]
WO WO2006133398A2 · 2006 [cited by applicant]
WO WO2010099301A1 · 2010 [cited by applicant]
WO WO2010141989A1 · 2010 [cited by applicant]
WO WO2013049275A1 · 2013 [cited by applicant]
WO WO2013154760A1 · 2013 [cited by applicant]
WO WO2014100615A1 · 2014 [cited by applicant]
WO WO2015142675A2 · 2015 [cited by applicant]
WO WO2015158671A1 · 2015 [cited by applicant]
WO WO2016014565A2 · 2016 [cited by applicant]
WO WO2016014789A2 · 2016 [cited by applicant]
WO WO2016089916A1 · 2016 [cited by applicant]
WO 2017025038A1 · 2017 [cited by applicant]
WO WO2017062451A1 · 2017 [cited by applicant]
WO WO2017147383A1 · 2017 [cited by applicant]
WO WO2018014038A1 · 2018 [cited by applicant]
WO WO2018014039A1 · 2018 [cited by applicant]
WO WO2018052828A1 · 2018 [cited by applicant]
WO WO2018119215A1 · 2018 [cited by applicant]
WO WO2019126574A1 · 2019 [cited by applicant]
WO WO2019173636A9 · 2020 [cited by applicant]
WO WO2021127505A1 · 2021 [cited by applicant]
WO WO2021211628A1 · 2021 [cited by applicant]
US 5,733,746 A, 03/1998, Treco et al. (withdrawn) [cited by applicant]
Islam et al., Cells 2021, 10:1058. [cited by examiner]
Cohen, A. (Dec. 12, 2019) Myeloma: next generation immunotherapy. American Society of Hematology (Dec. 12, 2019) 2019(1): 266-272. [cited by applicant]
Cohen, A. et al. (Feb. 11, 2019) Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine-Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma. Cancer immunology research 7(4): 658-669. [cited by applicant]
Cohen, A. et al. (Mar. 21, 2019) B cell maturation antigen-specific CART cells are clinically active in multiple myeloma. The Journal of clinical investigation 129(6): 2210-2221. [cited by applicant]
Costello C L et al (2019) “Phase 2 study of the response and safety of P-Bcma-101 CAR-T cells in patients with relapsed/refractory (r/r) multiple myeloma (MM)(PRIME)” Blood, 134: 3184, 3 pages. [cited by applicant]
Costello C L et al (2020) “Phase 1/2 study of the safety and response of P-BCMA-101 CAR-T cells in patients with relapsed/refractory (r/r) multiple myeloma (MM)(PRIME) with novel therapeutic strategies” Blood, 136: 29-3… [cited by applicant]
Database STN, CAS Registry No. RN 195514-63-7, “2-Piperidinecarboxylic acid, 1-[(2S)-1-oxo-2-(3,4,5-trimethoxyphenyl)butyl]-, 2,2′-[1,2-ethanediylbis[imino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylene[(1R)-3-(3,4-dimethoxyphe… [cited by applicant]
Database STN, CAS Registry No. 195514-80-8, “2-Piperidinecarboxylic acid, 1-[(2S)-1-oxo-2-(3,4,5-trimethoxyphenyl)butyl]-, 2,2′-[[2-[(dimethylamino)methyl]-1,3-propanediyl]bis[imino(2-oxo-2,1-ethanediyl)oxy-3,1-phenylen… [cited by applicant]
Kapoor P et al (2008) “Anti-CD20 monoclonal antibody therapy in multiple myeloma” British Journal of Haematology, 141(2): 135-148. [cited by applicant]
Mariuzza, et al., “The Structural Basis of Antigen-antibody Recognition,” Annual Review of Biophysics and Biophysical Chemistry, 1987, vol. 16.1: 139-159. [cited by applicant]
Perez-Amill L et al. (2018) “CAR-T cell therapy: a door is open to find innumerable possibilities of treatments for cancer patients” Turkish Journal of Hematology, 35(4): 217-228. [cited by applicant]
Quintarelli, C. et al. (Oct. 15, 2007) “Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes” Blood, 110(8):2793-2802 [online]. Retrieved from the Inte… [cited by applicant]
Roitt et al. (2000) “Chapter 20: Tumor Immunology,” Immunology 5th edition, pp. 273-283; English Translation, Moscow:Mir, pp. 387-390. [cited by applicant]
Ron et al. (1991) “Angiotensinogen gene-inducible enhancer-binding protein 1, a member of a new family of large nuclear proteins that recognize nuclear factor kappa B-binding sites through a zinc finger motif” Molecular… [cited by applicant]
Sohail A et al (2018) “Emerging immune targets for the treatment of multiple myeloma” Immunotherapy, 10(4): 265-282. [cited by applicant]
Straathof, K.C. et al. (2005) “An inducible caspase 9 safety switch for T-cell therapy” Blood, 105:4247-4254. [cited by applicant]
Abbas A. K., et al., “Functional diversity of helper T lymphocytes,” Nature, 1996 vol. 383, No. 6603. pp. 787-793. [cited by applicant]
Barnett, B.E. et al. (Dec. 2, 2016) “piggyBac-Produced CAR-T Cells Exhibit Stem-Cell Memory Phenotype” Blood, 128(22):2167, 5 pages. [cited by applicant]
Barnett et al. “Development of novel non-immunoglobulin centyrin-based cars (CARTyrins) targeting human Bcma”, Blood, (2016); 128(22):4557, 3 pages. [cited by applicant]
Berdeja et al. “Clinical remissions and limited toxicity in a first-in-human multicenter study of bb2121, a novel anti-BCMA Car T cell therapy for relapsed/refractory multiple myeloma”, European Journal of Cancer, (2016… [cited by applicant]
Bødker et al. “A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis”, Blood Advances, (2018); 2(18):2400-2411. [cited by applicant]
Brentjens et al. “Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias”, Blood, (2011); 118(18):4817-4828. [cited by applicant]
Brentjens et al. “CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia”, Science Translational Medicine, (2013); 5(177):177ra38, 10 pages. [cited by applicant]
Brudno et al. “Toxicities of chimeric antigen receptor T cells: recognition and management”, Blood, The Journal of the American Society of Hematology, (2016); 127(26):3321-3330. [cited by applicant]
Cavo et al. “Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group”, The Lancet Oncology, (2017); 18… [cited by applicant]
Cohen et al. “B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) for multiple myeloma (MM): initial safety and efficacy from a phase I study”, Blood, (2016); 128(22):1147, 4 pages. [cited by applicant]
Cunningham et al. “Modeling correction of severe urea cycle defect in the growing murine liver using a hybrid recombinant Adeno-associated virus/ PiggyBac transposase gene delivery system”, Hepatology, (2015); 62(2):417… [cited by applicant]
Di Stasi et al., “Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy”. N Engl J Med. Nov. 3, 2011; 365(18): 1673-1683. [cited by applicant]
Engelhardt et al. “Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches”, Leukemia & Lymphoma, (2010); 51(8): 1424-1443. [cited by applicant]
Fink et al. “The novel mechanism of lenalidomide activity”, Blood, The Journal of the American Society of Hematology, (2015); 126(21):2366-2369. [cited by applicant]
Flores-Montero et al. “Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma”, Cytometry Part B: Clinical Cytometry, (2016); 90(1):61-72. [cited by applicant]
Fostier et al. “Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation”, Oncotarget, (2018); 9(29):20476-20489. [cited by applicant]
Fraser et al. “Precise excision of TTAA-specific lepidopteran transposons piggyBac (IFP2) and tagalong (TFP3) from the baculovirus genome in cell lines from two species of Lepidoptera”, Insect Molecular Biology, 1996; 5… [cited by applicant]
Frey et al. “CAR T-cells merge into the fast lane of cancer care”, American Journal of Hematology, (2016); 91(1):146-150. [cited by applicant]
Hackett et al. “Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy”, Translational Research, (2013); 161(4):265-283. [cited by applicant]
Hermanson et al. “A novel BCMA-specific, centyrin-based CAR-T product for the treatment of multiple myeloma”, Blood, (2016); 128(22):2127, 3 pages. [cited by applicant]
Howlader et al. “SEER Cancer Statistics Review, 1975-2012”, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2012/, based on Nov. 2014 SEER data submission, posted to the SEER web site, Apr. 2015… [cited by applicant]
Huls et al. “Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood”, JoVE (Journal of Visualized Experiments), (2013); (72… [cited by applicant]
Jena, B. et al. “Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor” Blood, (Aug. 19, 2010); 116(7):1035-1044. [cited by applicant]
Johnsen et al. “The myeloma stem cell concept, revisited: from phenomenology to operational terms. Haematologica”, (2016); 101(12):1451-1459. [cited by applicant]
Kapoor et al. “Outcome of Children with Primary Immune-Deficiencies (PIDs) enrolled in a phase I-II trial based on the infusion of BPX-501 donor t cells genetically modified with a novel suicide gene (inducible Caspase … [cited by applicant]
Kochenderfer, JN. “Chimeric antigen receptors/genetically modified T-cells”, Blood, (2016); 128(22):SCI-37, 2 pages. [cited by applicant]
Kumar et al. “Improved survival in multiple myeloma and the impact of novel therapies”, Blood, (2008); 111(5):2516-2520. [cited by applicant]
Kumar et al., “International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.” The Lancet Oncology 17.8 (2016): e328-e346. [cited by applicant]
Kumar et al. “Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study”, Leukemia, (2012); 26(1):149-157. [cited by applicant]
Lee et al. “Current concepts in the diagnosis and management of cytokine release syndrome”, Blood, The Journal of the American Society of Hematology, (2014); 124(2):188-195. [cited by applicant]
Lenalidomide (REVLIMID®) US Prescribing Information, May 2019, 28 pages. https://media.celgene.com/content/uploads/revlimid-pi.pdf. [cited by applicant]
Matsui et al. “Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance”, Cancer Research, (2008); 68(1):190-197. [cited by applicant]
Milone et al. “Acute GVHD after allogeneic hematopoietic transplantation affects early marrow reconstitution and speed of engraftment”, Experimental Hematology, (2015); 43(6):430-438. [cited by applicant]
Moreau et al. “Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide”, Blood Cancer Journal, (2019); 9(4):38, 8 pages. [cited by applicant]
Mossine et al. “piggyBac transposon plus insulators overcome epigenetic silencing to provide for stable signaling pathway reporter cell lines”, PloS One, (2013); 8(12):e85494, 12 pages. [cited by applicant]
Nakazawa, Y. et al. “Evaluation of long-term transgene expression in piggyBac-modified human T lymphocytes” J Immunotherapy, (Jan. 2013); 36(1):3-10. [cited by applicant]
Otáhal et al. “Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells”, Oncoimmunology, (2016); 5(4):e1115940, 11 pages. [cited by applicant]
Pegram et al. “Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning”, Blood, The Journal of the American Society of Hematology, (2012); 119(18):4133-4141. [cited by applicant]
Rabb et al. “Recent advances in the biology and treatment of multiple myeloma”, Lancet, (2009); 374:324-339. [cited by applicant]
Rajkumar et al. “Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1”, Blood, (2011); 117(18):4691-4695. [cited by applicant]
Rajkumar et al. “International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma”, The Lancet Oncology, (2014); 15(12):e538-e548. [cited by applicant]
Rushworth et al. “Antithymidylate resistance enables transgene selection and cell survival for T cells in the presence of 5-fluorouracil and antifolates”, Gene Therapy, (2016); 23(2):119-128. [cited by applicant]
Salles et al. “Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience”, Advances in Therapy, (2017); 34:2232-2273. [cited by applicant]
Singh et al. “Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells”, PloS One, (2013); 8(5):e64138, 11 page… [cited by applicant]
Tai et al. “Targeting B-cell maturation antigen in multiple myeloma”, Immunotherapy, (2015); 7(11):1187-1199. [cited by applicant]
Tey “Adoptive T-cell therapy: adverse events and safety switches”, Clinical & Translational Immunology, (2014); 3(6):e17, 7 pages. [cited by applicant]
Thomis et al “A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease”, Blood, The Journal of the American Society of Hematology, (2001); 97(5):1249-1257. [cited by applicant]
Wang et al. “Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple Myeloma”, Clinical Cancer Research, (2018); 24(1):106-119. [cited by applicant]
Woodard et al. “piggyBac-ing models and new therapeutic strategies”, Trends in Biotechnology, (2015); 33(9):525-533. [cited by applicant]
Works et al. “Anti-B-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide”, Molecular Cancer Therapeutics, (2019); 18(12):2246-2257. [cited by applicant]
Xu et al. “Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma”, Proceedings of the National Academy of Sciences, (2019); 116(19):9543-9551. [cited by applicant]
Yutaka et al. “Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma”, Leukemia & Lymphoma, (2015); 56(11):3216-3218. [cited by applicant]
Zhou et al. “iCaspase 9 suicide gene system”, Gene Therapy of Solid Cancers: Methods and Protocols, (2015): 87-105. [cited by applicant]
Zhou et al. “Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation”, Blood, The Journal of the American Society of Hematology, (2015); 125(26):… [cited by applicant]
Zhou, X. et al. “Improving the safety of T-Cell therapies using an inducible caspase-9 gene” Experimental Hematology, (2016); 44(11):1013-1019. [cited by applicant]
Carpenter, R.O. et al. (Apr. 15, 2013), “B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma” Clinical Cancer Research, 19(8):2048-2060. [cited by applicant]
Wang, L. et al. (Apr. 2015) “Application of CAR-T/NK Cells modified by chimeric antigen receptor in the Treatment of Multiple Myeloma” [Chinese]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 23(2):568-72. (Abstract). [cited by applicant]
Abate-Daga, D. et al. (Jan. 1, 2016) “CAR models: next-generation CAR modifications for enhanced T-cell function” [cited by applicant]
Alabanza, L. et al. (2017) “Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains” [cited by applicant]
Ali, S.A. et al. (Sep. 29, 2016) “T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma” [cited by applicant]
Anonymous: “Poseida Therapeutics, Inc. Announces Worldwide License Agreement with Janssen to Apply Centyrin Technology in the Development of Chimeric Antigen Receptor (CAR) Therapies—Poseida Therapeutics” Aug. 11, 2015.… [cited by applicant]
Arcone, R. et al. (1988) “Identification of sequences responsible for acute-phase induciton of human C-reactive protein” [cited by applicant]
Bojak, A. et al. (2002) “Muscle specific versus ubiquitous expression of Gag based HIV-1 DNA vaccines: a comparative analysis” [cited by applicant]
Burns, W.R. et al. (Apr. 2010) “A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas” [cited by applicant]
Capellas, M. et al. (1997) “Enzymatic Condensation of Cholecystokinin CCK-8 (4-6) and CCK-8 (7-8) Peptide Fragments in Organic Media” [cited by applicant]
Cazeaux, N. et al. (2002) “Comparative study of immune responses induced after immunization with plasmids encoding the HIV-1 Nef protein under the control of the CMV-IE or the muscle-specific desmin promoter” [cited by applicant]
Chmielewski, M. et al. (May 18, 2015) “TRUCKs: the fourth generation of CARs” [cited by applicant]
Cordoba, S.-P. et al. (May 2013) “The large ectodomains of CD45 and CD148 regulate their segregation from and inhibition of ligated T-cell receptor” Blood, 121(21):4295-4302. [cited by applicant]
Cunningham, B.C. and J.A. Wells (Jun. 2, 1989) “High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis” [cited by applicant]
De Vos, A.M. et al. (1992) “Human Growth Hormone and Extracellular Domain of Its Receptor: Crystal Structure of the Complex” [cited by applicant]
Diem, M.D. et al. (Apr. 30, 2014) “Selection of high-affinity Centyrin FN3 domains from a simple library diversified at a combination of strand and loop positions” [cited by applicant]
Donnelly, J.J. et al. (1997) “DNA Vaccines” [cited by applicant]
Fisch, I. et al. (1992) “Site-Specific Modification of a Fragment of a Chimeric Monoclonal Antibody Using Reverse Proteolysis” [cited by applicant]
Gossen, M. and H. Bujard (Jun. 1992) “Tight control of gene expression in mammalian cells by tetracycline-responsive promoters” [cited by applicant]
Gossen, M. et al. (Jun. 23, 1995) “Transcriptional activation by tetracyclkines in mammalian cells” [cited by applicant]
Itoh, K. et al. (1996) “Application of Inverse Substrates to Trypsin-Catalyzed Peptide Synthesis” [cited by applicant]
Iuliucci, J.D. et al. (2001) “Intravenous Safety and Pharmacokinetics of a Novel Dimerizer Drug, API903, in Healthy Volunteers” [cited by applicant]
Junginger, H.E. et al. (1994) “Visualization of Drug Transport Across Human Skin and the Influence of Penetration Enhancers” in [cited by applicant]
Kageyama, R. et al. (Feb. 15, 1987) “Differing Utilization of Homologous Transcription Initiation Sites of Rat K and T Kininogen Genes Under Inflammation Condition” J Biol Chem, 262(5):2345-2351. [cited by applicant]
Kumaran, S. et al. (1997) “Conformationally driven protease-catalyzed splicing of peptide segments: V8 protease-mediated synthesis of fragments derived from thermolysin and ribonuclease A” [cited by applicant]
Maus, M.V. et al. (Apr. 24, 2014) “Antibody-modified T cells: CARs take the front seat for hematologic malignancies” [cited by applicant]
Oliviero, S. et al. (1987) “The human haptoglobin gene: transcriptional regulation during development and acute phase induction” [cited by applicant]
Philip, B. et al. (Aug. 21, 2014) “A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy” [cited by applicant]
Poli, V. and R. Cortese (Nov. 1989) “Interleukin 6 induces a liver-specific nuclear protein that binds to the promoter of acute-phase genes” [cited by applicant]
Prowse, K.R. and H. Baumann (Jan. 1988) “Hepatocyte-Stimulating Factor, β2 Interferon, and Interleukin-1 Enhance Expression of the Rat α [cited by applicant]
Smith, L.J. et al. (1992) “Human Interleukin 4. The Solution Structure of a Four-helix Bundle Protein” [cited by applicant]
Sprague, J. et al. (Feb. 1983) “Expression of a Recombinant DNA Gene Coding for the Vesicular Stomatitis Virus Nucleocapsid Protein” [cited by applicant]
Stepanov, A.V. et al., Modeling ligandreceptor interactions in detection mode on the surface of a single cell, Biological membranes: Journal of membrane and cell biology, 2015, V. 32, N. 2, pp. 102-109 [Russian, English… [cited by applicant]
Werlen, R.C. et al. (1994) “Site-Specific Conjugation of an Enzyme and an Antibody Fragment” [cited by applicant]
Wilson, D.R. et al. (Dec. 1990) “A 58-Base-Pair Region of the Human C3 Gene Confers Synergistic Inducibility by Interleukin-1 and Interleukin-6” [cited by applicant]
Zechner, R. et al. (Jun. 1988) “Recombinant Human Cachectin/Tumor Necrosis Factor but Not Interleukin-1α Downregulates Lipoprotein Lipase Gene Expression at the Transcriptional Level in Mouse 3T3-L1 Adipocytes” [cited by applicant]
GenBank Accession No. AB179012.1 (Oct. 6, 2006) “Macaca fascicularis testis cDNA clone: QtsA-11460, similar to human piggyBac transposable element derived 3 (PGBD3), mRNA, RefSeq: NM_170753.1” Bethesda (MD): National Li… [cited by applicant]
GenBank Accession No. EU287451.1 (Mar. 1, 2008) “Macdunnoughia crassisigna transposon piggyBac McrPLE, complete sequence” Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information [… [cited by applicant]
GenBank Accession No. GU270322.1 (Jan. 19, 2010) “Pectinophora gossypiella transposon piggyBac-like element PgPLE1.1 transposase gene, complete cds” Bethesda (MD): National Library of Medicine (US), National Center for … [cited by applicant]
GenBank Accession No. GU329918.1 (Dec. 31, 2010) “Aphis gossypii transposon piggyBac-like element AgoPLE1.1 transposase gene, complete cds” Bethesda (MD): National Library of Medicine (US), National Center for Biotechno… [cited by applicant]
GenBank Accession No. GU477713.1 (Mar. 8, 2011) “Ctenoplusia agnata transposon piggyBac-like element PLE1.1 transposase gene, complete cds” Bethesda (MD): National Library of Medicine (US), National Center for Biotechno… [cited by applicant]
GenBank Accession No. GU477714.1 (Mar. 8, 2011) “Agrotis ipsilon transposon piggyBac-like element PLE1.1 transposase gene, complete cds” Bethesda (MD): National Library of Medicine (US), National Center for Biotechnolog… [cited by applicant]
GenBank Accession No. JX294476.1 (Jan. 30, 2015) “Chilo suppressalis transposon piggyBac-like element transposase (PLE1.1) gene, complete cds” Bethesda (MD): National Library of Medicine (US), National Center for Biotec… [cited by applicant]
GenPept Accession No. AAA87375.2 (Oct. 15, 2002) “unknown protein [ [cited by applicant]
GenPept Accession No. AAL39784.1 (Dec. 17, 2001) “LD40589p [ [cited by applicant]
GenPept Accession No. AAM76342.1 (Dec. 20, 2002) “putative transposase [Daphnia pulicaria]” Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information [online]. Retrieved from: https… [cited by applicant]
GenPept Accession No. ABD76335.1 (Aug. 3, 2006) “transposase [Heliothis virescens]” Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information [online]. Retrieved from: https://www.n… [cited by applicant]
GenPept Accession No. ABS18391.1 (Mar. 17, 2008) “transposase [Helicoverpa armigera]” Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information [online]. Retrieved from: https://www… [cited by applicant]
GenPept Accession No. BAD11135.1 (Sep. 15, 2007) “putative transposase yabusame-1 [Bombyx mori]” Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information [online]. Retrieved from: … [cited by applicant]
GenPept Accession No. BAF82026.1 (Sep. 9, 2008) “piggyBac transposase Uribo2 [Xenopus tropicalis]” Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information [online]. Retrieved from… [cited by applicant]
GenPept Accession No. NP_689808.2 (May 2, 2019) “piggyBac transposable element-derived protein 4 [ [cited by applicant]
GenPept Accession No. NP_741958.1 (Mar. 29, 2020) “piggyBac transposable element-derived protein 5 [Mus musculus]” Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information [online]… [cited by applicant]
GenPept Accession No. XP_001814566.1 (Jul. 21, 2008) “PREDICTED: similar to PiggyBac transposable element-derived protein 4 [Tribolium castaneum]” Bethesda (MD): National Library of Medicine (US), National Center for Bi… [cited by applicant]
GenPept Accession No. XP_001948139.1 (Jul. 2, 2008) “PREDICTED: similar to PiggyBac transposable element-derived protein 4 [Acyrthosiphon pisum]” Bethesda (MD): National Library of Medicine (US), National Center for Bio… [cited by applicant]
GenPept Accession No. XP_002123602.1 (Oct. 24, 2014) “PREDICTED: piggyBac transposable element-derived protein 4-like [Ciona intestinalis]” Bethesda (MD): National Library of Medicine (US), National Center for Biotechno… [cited by applicant]
GenPept Accession No. XP_220453.3 (Apr. 15, 2005) “PREDICTED: similar to piggyBac transposable element derived 2 [Rattus norvegicus]” Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology I… [cited by applicant]
GenPept Accession No. XP_310729.1 (Apr. 26, 2018) “AGAP000379-PA [ [cited by applicant]
GenPept Accession No. XP_312615.1 (Apr. 26, 2018) “AGAP002349-PA [ [cited by applicant]
GenPept Accession No. XP_320414.1 (Apr. 26, 2018) “AGAP012114-PA [ [cited by applicant]
Badri et al., “Optimization of radiation dosing schedules for proneural glioblastoma,” J Math Biol., (Apr. 2016); 72(5):1301-1336 (Abstract only), 1 page. [cited by applicant]
Baylot et al., “TCTP Has a Crucial Role in the Different Stages of Prostate Cancer Malignant Progression,” Results Probl Cell Differ., (Nov. 2017); 64:255-261 (Abstract only), 1 page. [cited by applicant]
Tong et al., “CAR Technology and its application in treatment of multiple myeloma” Review, Chinese Journal of Experimental Hematology 24(1):279-284, with English Google machine translation (2016), 12 pages. [cited by applicant]